OverviewSuggest Edit
Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
| Type | Public | |
| Founded | 2012 | |
| HQ | San Carlos, US | Map |
| Website | allakos.com |
Latest Updates
| Employees (est.) (Feb 2019) | 51 | (+16%) |
| Share Price (May 2019) | $44 | (-1%) |
Key People/Management at Allakos
Christopher Bebbington
Founder
Nenad Tomasevic
Vice President of Research
Allakos Office Locations
Allakos has an office in San Carlos
San Carlos, US (HQ)
75 Shoreway Rd Suite A
Allakos Financials and Metrics
Allakos Revenue
| USD | |
|---|---|
Net income (FY, 2018) | (43.5m) |
EBIT (FY, 2018) | (45.7m) |
Market capitalization (22-May-2019) | 1.9b |
Closing stock price (22-May-2019) | 44.0 |
Cash (30-Sep-2018) | 51.6m |
Allakos's current market capitalization is $1.9 b.
Annual
Annual
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.1 x |
Allakos News and Updates
May 08, 2019
Allakos Reports First Quarter 2019 Financial Results
REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019.
Allakos Blogs
March 14, 2019
Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
Content Import
Thu, 03/14/2019 - 16:03
Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
March 14, 2019 at 4:01 PM EDT
…
February 19, 2019
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
Content Import
Tue, 02/19/2019 - 08:13
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
February 19, 2019 at 8:00 AM EST
This release…
February 11, 2019
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
Janice.Nispero…
Mon, 02/11/2019 - 08:10
Allakos Announces Positive Phase 2 Results for AK002 in Patients w…
January 07, 2019
Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
Content Import
Mon, 01/07/2019 - 08:14
Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
January 7, 2019 …
November 08, 2018
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
Content Import
Thu, 11/08/2018 - 16:04
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
November 8, 2018 at 4:01 PM EST
This release is a backfill from a News …
October 08, 2018
Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
SAN CARLOS, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced the presentation of two posters at the American College
Allakos Frequently Asked Questions
When was Allakos founded?
Allakos was founded in 2012.
Who are Allakos key executives?
Allakos's key executives are Christopher Bebbington and Nenad Tomasevic.
How many employees does Allakos have?
Allakos has 51 employees.
Who are Allakos competitors?
Competitors of Allakos include Sosei Heptares, CinCor Pharma and Seres Therapeutics.
Where is Allakos headquarters?
Allakos headquarters is located at 75 Shoreway Rd Suite A, San Carlos.
Where are Allakos offices?
Allakos has an office in San Carlos.
How many offices does Allakos have?
Allakos has 1 office.